- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07943377
Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Aligos Therapeutics
- Numéro de téléphone: 800-466-6059
- E-mail: info@aligos.com
Lieux d'étude
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53704
- Aligos Investigational Site
-
Contact:
- Aligos Investigational Site
- Numéro de téléphone: 800-466-6059
- E-mail: info@aligos.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria: Key Inclusion Criteria
- Parts A and B only: Male or female between 18 and 60 years of age
- Part C only: Males between 18 and 55 years of age.
- Body mass index between 18.0 kg/m2 and 32.0 kg/m2
- In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
- Part C only: History of a minimum of 1 bowel movement per day.
Exclusion Criteria: Key Exclusion Criteria:
-
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
-
History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).
-
History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.
-
Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.
-
Positive hepatitis panel and/or positive human immunodeficiency virus test.
-
Parts A and B only: Any of the following at screening or check-in:
- QTcF >450 ms in males or >470 ms in females
- QRS duration >120 ms
- PR interval >210 ms
- findings which would make QTc measurements difficult or QTc data uninterpretable
-
Administration of any vaccine within 30 days prior to dosing.
-
Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing
-
Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.
-
Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: ALG-000184
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of ALG-000184 |
|
Comparateur placebo: Placebo
Oral tablet(s) of placebo in HV participants once daily for up to 10 days |
Single or multiple doses of Placebo |
|
Autre: [14C]ALG-000184
|
Single oral dose of [14C]ALG-000184 Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety and Tolerability (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including AUC0-τ |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including tmax t1/2 |
From enrollment to end of treatment at 10 days
|
|
PK Parameters (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters of ALG-001075 and ALG-000302, including ARAUC |
From enrollment to end of treatment at 10 days
|
|
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Délai: From enrollment to end of treatment at 10 days
|
determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Metabolic profiles of ALG-000184 (Part C)
Délai: From enrollment to end of treatment at 10 days
|
Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Identification of ALG-000184 (Part C)
Délai: From enrollment to end of treatment at 10 days
|
Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184 |
From enrollment to end of treatment at 10 days
|
|
Bioavailability of ALG-001075 (Part C)
Délai: From enrollment to end of treatment at 10 days
|
Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075 |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞ |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax |
From enrollment to end of treatment at 10 days
|
|
PK parameters (Part C)
Délai: From enrollment to end of treatment at 10 days
|
PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2 |
From enrollment to end of treatment at 10 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
QTc (Part A and B)
Délai: From enrollment to end of treatment at 10 days
|
Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants |
From enrollment to end of treatment at 10 days
|
|
Safety and Tolerability (Part C)
Délai: From enrollment to end of treatment at 10 days
|
Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results |
From enrollment to end of treatment at 10 days
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- ALG-000184-209
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .